Immunologic responses during sepsis vary significantly among patients and evolve over the course of illness. Sepsis has a direct impact on the immune system due to adverse alteration of the production, maturation, function, and apoptosis of immune cells. Dysregulation in both the innate and adaptive immune responses during sepsis leads to a range of phenotypes consisting of both hyperinflammation and immunosuppression that can result in immunoparalysis. In this review, we discuss components of immune dysregulation in sepsis, biomarkers and functional immune assays to aid in immunophenotyping patients, and evolving immunomodulatory therapies. Important research gaps for the future include: (1) Defining how age, host factors including prior exposures, and genetics impact the trajectory of sepsis in children, (2) Developing tools for rapid assessment of immune function in sepsis, and (3) Assessing how evolving pediatric sepsis endotypes respond differently to immunomodulation. Although multiple promising immunomodulatory agents exist or are in development, access to rapid immunophenotyping will be needed to identify which children are most likely to benefit from which therapy. Advancements in the ability to perform multidimensional endotyping will be key to developing a personalized approach to children with sepsis.
Immunologic responses during sepsis vary significantly among patients and evolve over the course of illness. The resulting spectrum of immunoparalysis that can occur due to sepsis can increase morbidity and mortality in children and adults.
This narrative review summarizes the current literature surrounding biomarkers and functional immunologic assays for immune dysregulation in sepsis, with a focus on immunomodulatory therapies that have been evaluated in sepsis.
A precision approach toward diagnostic endotyping and therapeutics, including gene expression, will allow for optimal clinical trials to evaluate the efficacy of individualized and targeted treatments for pediatric sepsis.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Pediatric Research Open Access 19 January 2022
Subscribe to Journal
Get full journal access for 1 year
only $9.15 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Singer, M. et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMAama 315, 801–810 (2016).
Fleischmann-Struzek, C. et al. The global burden of paediatric and neonatal sepsis: a systematic review. Lancet Respir. Med. 6, 223–230 (2018).
Weiss, S. L. et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am. J. Respir. Crit. Care Med. 191, 1147–1157 (2015).
Simon, A. K., Hollander, G. A. & McMichael, A. Evolution of the immune system in humans from infancy to old age. Proc. Biol. Sci. 282, 20143085 (2015).
Georgountzou, A. & Papadopoulos, N. G. Postnatal innate immune development: from birth to adulthood. Front. Immunol. 8, 957 (2017).
Wynn, J., Cornell, T. T., Wong, H. R., Shanley, T. P. & Wheeler, D. S. The host response to sepsis and developmental impact. Pediatrics 125, 1031–1041 (2010).
Delano, M. J. & Ward, P. A. The immune system’s role in sepsis progression, resolution, and long-term outcome. Immunol. Rev. 274, 330–353 (2016).
Chen, X.-H., Yin, Y.-J. & Zhang, J.-X. Sepsis and immune response. World J. Emerg. Med. 2, 88–92 (2011).
Medzhitov, R. & Janeway, C. Jr Innate immunity. N. Engl. J. Med. 343, 338–344 (2000).
Chousterman, B. G., Swirski, F. K. & Weber, G. F. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 39, 517–528 (2017).
Delano, M. J. & Ward, P. A. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J. Clin. Investig. 126, 23–31 (2016).
Kolaczkowska, E. & Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13, 159–175 (2013).
Kaplan, M. J. & Radic, M. Neutrophil extracellular traps: double-edged swords of innate immunity. J. Immunol. 189, 2689–2695 (2012).
Winkler, M. S. et al. Human leucocyte antigen (HLA-DR) gene expression is reduced in sepsis and correlates with impaired TNFα response: a diagnostic tool for immunosuppression? PLoS ONE 12, e0182427 (2017).
Boomer, J. S. et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306, 2594–2605 (2011).
Cao, C., Ma, T., Chai, Y.-F. & Shou, S.-T. The role of regulatory T cells in immune dysfunction during sepsis. World J. Emerg. Med. 6, 5–9 (2015).
Monserrat, J. et al. Early alterations of B cells in patients with septic shock. Crit. Care 17, R105 (2013).
Chousterman, B. G. & Swirski, F. K. Innate response activator B cells: origins and functions. Int. Immunol. 27, 537–541 (2015).
Martin, M. D., Badovinac, V. P. & Griffith, T. S. CD4 T cell responses and the sepsis-induced immunoparalysis state. Front. Immunol. 11, 1364 (2020).
Jensen, I. J., Sjaastad, F. V., Griffith, T. S. & Badovinac, V. P. Sepsis-induced T cell immunoparalysis: the ins and outs of impaired T cell immunity. J. Immunol. 200, 1543–1553 (2018).
Doughty, L., Carcillo, J. A., Kaplan, S. & Janosky, J. The compensatory anti-inflammatory cytokine interleukin 10 response in pediatric sepsis-induced multiple organ failure. Chest 113, 1625–1631 (1998).
Wynn, J. L. et al. Increased mortality and altered immunity in neonatal sepsis produced by generalized peritonitis. Shock 28, 675–683 (2007).
Barsness, K. A. et al. Endotoxin induces an exaggerated interleukin-10 response in peritoneal macrophages of children compared with adults. J. Pediatr. Surg. 39, 912–915 (2004).
Muszynski, J. A. et al. Early adaptive immune suppression in children with septic shock: a prospective observational study. Crit. Care 18, R145 (2014).
Muszynski, J. A. et al. Early immune function and duration of organ dysfunction in critically iii children with sepsis. Am. J. Respir. Crit. Care Med. 198, 361–369 (2018).
Remy, S. et al. Occurrence of marked sepsis-induced immunosuppression in pediatric septic shock: a pilot study. Ann. Intensive Care 8, 36 (2018).
Skirecki, T., Borkowska-Zielinska, U., Zlotorowicz, M. & Hoser, G. Sepsis immunopathology: perspectives of monitoring and modulation of the immune disturbances. Arch. Immunol. Ther. Exp. 60, 123–135 (2012).
Chaudhry, H. et al. Role of cytokines as a double-edged sword in sepsis. Vivo 27, 669–684 (2013).
Gogos, C. A., Drosou, E., Bassaris, H. P. & Skoutelis, A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 181, 176–180 (2000).
Hotchkiss, R. S. et al. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J. Immunol. 174, 5110–5118 (2005).
Girardot, T., Rimmele, T., Venet, F. & Monneret, G. Apoptosis-induced lymphopenia in sepsis and other severe injuries. Apoptosis 22, 295–305 (2017).
Drewry, A. M. et al. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock 42, 383–391 (2014).
Felmet, K. A., Hall, M. W., Clark, R. S., Jaffe, R. & Carcillo, J. A. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J. Immunol. 174, 3765–3772 (2005).
Monneret, G. & Venet, F. Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy. Cytom. B Clin. Cytom. 90, 376–386 (2016).
Boomer, J. S., Shuherk-Shaffer, J., Hotchkiss, R. S. & Green, J. M. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit. Care 16, R112 (2012).
Guignant, C. et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit. Care 15, R99 (2011).
Monneret, G. et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 32, 1175–1183 (2006).
Benlyamani, I., Venet, F., Coudereau, R., Gossez, M. & Monneret, G. Monocyte HLA-DR measurement by flow cytometry in COVID-19 patients: an interim review. Cytom. A 97, 1217–1221 (2020).
Manzoli, T. F., Troster, E. J., Ferranti, J. F. & Sales, M. M. Prolonged suppression of monocytic human leukocyte antigen-DR expression correlates with mortality in pediatric septic patients in a pediatric tertiary intensive care unit. J. Crit. Care 33, 84–89 (2016).
Hall, M. W. et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 37, 525–532 (2011).
Hall, M. W. et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit. Care Med. 41, 224–236 (2013).
Liddiard, K. & Taylor, P. R. Understanding local macrophage phenotypes in disease: shape-shifting macrophages. Nat. Med. 21, 119–120 (2015).
The Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections: a double-blind study. JAMA 183, 462–465 (1963).
Ono, S., Tsujimoto, H., Hiraki, S. & Aosasa, S. Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis. Ann. Gastroenterol. Surg. 2, 351–358 (2018).
Tuttle, K. M., McDonald, M. D. & Anderson, E. J. Re-evaluating biologic pharmacotherapies that target the host response during sepsis. Int. J. Mol. Sci. 20, 6049 (2019).
Nedeva, C., Menassa, J. & Puthalakath, H. Sepsis: inflammation is a necessary evil. Front. Cell Dev. Biol. 7, 108 (2019).
Hawchar, F. et al. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J. Crit. Care 49, 172–178 (2019).
Lin, W. T., Lai, C. C., Wang, J. J. & Chao, C. M. Effect of polymyxin B hemoperfusion on the outcome of patients with sepsis and septic shock. J. Infect. 80, 350–371 (2020).
CytoSorbents. Accessed December 22, 2021. https://cytosorbents.com/products/cyto-sorb/.
Fisher, C. J. Jr et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334, 1697–1702 (1996).
Fisher, C. J. Jr et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271, 1836–1843 (1994).
Shakoory, B. et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit. Care Med. 44, 275–281 (2016).
Cao, C., Yu, M. & Chai, Y. Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis. Cell Death Dis. 10, 782 (2019).
Hotchkiss, R. S. & Crouser, E. Imaging apoptosis in sepsis-A technology we would die for! Crit. Care Med. 43, 2506–2508 (2015).
Francois, B. et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 3, https://doi.org/10.1172/jci.insight.98960 (2018).
Steinhagen, F. et al. Immunotherapy in sepsis - brake or accelerate? Pharm. Ther. 208, 107476 (2020).
Guo, Y. et al. IL-15 enables septic shock by maintaining NK cell integrity and function. J. Immunol. 198, 1320–1333 (2017).
Romee, R. et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131, 2515–2527 (2018).
Payen, D. et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. BMC Infect. Dis. 19, 931 (2019).
Shao, R. et al. Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit. Care 20, 124 (2016).
Busch, L. M., Sun, J., Cui, X., Eichacker, P. Q. & Torabi-Parizi, P. Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis. Intensive Care Med. Exp. 8, 7 (2020).
Hotchkiss, R. S. et al. Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559). Crit. Care Med. 47, 632–642 (2019).
Mathias, B., Szpila, B. E., Moore, F. A., Efron, P. A. & Moldawer, L. L. A review of GM-CSF therapy in sepsis. Medicine 94, e2044 (2015).
Bo, L., Wang, F., Zhu, J., Li, J. & Deng, X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit. Care 15, R58 (2011).
Bilgin, K. et al. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 107, 36–41 (2001).
Carr, R., Modi, N. & Doré, C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst. Rev. 2003, CD003066 (2003).
Stanski, N. L. & Wong, H. R. Prognostic and predictive enrichment in sepsis. Nat. Rev. Nephrol. 16, 20–31 (2020).
Wong, H. R. et al. The pediatric sepsis biomarker risk model. Crit. Care 16, R174 (2012).
Wong, H. R. et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am. J. Respir. Crit. Care Med. 191, 309–315 (2015).
Abbas, M. & El-Manzalawy, Y. Machine learning based refined differential gene expression analysis of pediatric sepsis. BMC Med Genomics 13, 122 (2020).
Sweeney, T. E. et al. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit. Care Med. 46, 915–925 (2018).
Grunwell, J. R. et al. Machine learning-based discovery of a gene expression signature in pediatric acute respiratory distress syndrome. Crit. Care Explor 3, e0431 (2021).
Banerjee, S., Mohammed, A., Wong, H. R., Palaniyar, N. & Kamaleswaran, R. Machine learning identifies complicated sepsis course and subsequent mortality based on 20 genes in peripheral blood immune cells at 24 h post-ICU admission. Front. Immunol. 12, 592303 (2021).
We would like to thank the Program in Inflammation, Immunity and the Microbiome (PrIIMe) team and acknowledge the Lurie Children’s Immunology Lab. The following authors are supported by National Institutes of Health awards: NHLBI K08HL143127 (Coates), NIAID K08AI123524 (Arshad), and NIAID K23AI139337 (Mithal).
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mithal, L.B., Arshad, M., Swigart, L.R. et al. Mechanisms and modulation of sepsis-induced immune dysfunction in children. Pediatr Res 91, 447–453 (2022). https://doi.org/10.1038/s41390-021-01879-8
This article is cited by
Pediatric Research (2022)